ReviewMovement disorders : official journal of the Movement Disorder Society2016
Combination therapies: The next logical Step for the treatment of synucleinopathies?
Review in Movement disorders : official journal of the Movement Disorder Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Application of aptamers in regenerative medicine.Frontiers in bioengineering and biotechnology · 2022Pooled it
- Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Understanding alpha-synuclein aggregation propensity in animals and humans.Biochemistry and biophysics reports · 2024Article
- PPARs and Their Neuroprotective Effects in Parkinson's Disease: A Novel Therapeutic Approach in α-Synucleinopathy?International journal of molecular sciences · 2023Review
- Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- A new avenue for treating Parkinson's disease targeted at aggrephagy modulation and neuroinflammation: Insights from in vitro and animal studies.EBioMedicine · 2020Article
- Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model.Molecular therapy. Nucleic acids · 2019Article
- Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- Pharmacological Management of Dementia with Lewy Bodies.Drugs & aging · 2019Review
- Prion-Like Mechanisms in Parkinson's Disease.Frontiers in neuroscience · 2019Review
- The neuropathology of multiple system atrophy and its therapeutic implications.Autonomic neuroscience : basic & clinical · 2018Review
- Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- Prion-like propagation of pathology in Parkinson disease.Handbook of clinical neurology · 2018Review
- Editorial: Pathogenic templating proteins in Neurodegenerative Disease.Neurobiology of disease · 2018Article
- Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules.World journal of stem cells · 2017Review
- Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.Neurobiology of disease · 2017Article
- New Therapeutic Strategies for Lewy Body Dementias.Current neurology and neuroscience reports · 2017Review
- Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Journal of movement disorders · 2017Article
- Recombinant Antibody Fragments for Neurodegenerative Diseases.Current neuropharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Currently there are no disease-modifying alternatives for the treatment of most neurodegenerative disorders. The available therapies for diseases such as Parkinson's disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), in which the protein alpha-synuclein (α-Syn) accumulates within neurons and glial cells with toxic consequences, are focused on managing the disease symptoms. However, using strategic drug combinations and/or multi-target drugs might increase the treatment efficiency when compared with monotherapies. Synucleinopathies are complex disorders that progress through several stages, and toxic α-Syn aggregates exhibit prion-like behavior spreading from cell to cell. Therefore, it follows that these neurodegenerative disorders might require equally complex therapeutic approaches to obtain significant and long-lasting results. Hypothetically, therapies aimed at reducing α-Syn accumulation and cell-to-cell transfer, such as immunotherapy against α-Syn, could be combined with agents that reduce neuroinflammation with potential synergistic outcomes. Here we review the current evidence supporting this type of approach, suggesting that such rational therapy combinations, together with the use of multi-target drugs, may hold promise as the next logical step for the treatment of synucleinopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.